Multiple System Atrophy drug pipeline
2 compounds from 2 companies are in active clinical development for multiple system atrophy.
Mechanisms: Small molecule (2)
Pipeline data compiled October 2026 · every fact sourced.
Upcoming readouts & recent results
Anticipated Phase 2 (TOPAS-MSA) topline in multiple system atrophy (primary endpoint: change from baseline in UMSARS at week 48) ↗
Phase 3 CYPRESS did not meet its primary endpoint (change in OHSA composite score at Week 8 of the double-blind randomized-withdrawal period); secondary endpoints showed similar trends; consistent pressor effect, generally well tolerated, no supine-hypertension signal. ↗
REDWOOD Phase 3 did not meet its primary endpoint in the overall nOH population (PD, PAF, MSA); prespecified subgroup analysis suggested benefit driven by MSA patients. ↗
SEQUOIA 4-week Phase 3 RCT in symptomatic nOH did not meet its primary endpoint; no supine-hypertension signal. ↗
Compounds in development (2)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| EmrusolminOrphanFast Track | Teva Pharmaceutical Industries Ltd. | Phase 2 | Recruiting | Alpha-synuclein Modulator |
| AmpreloxetineFDA Orphan Drug Designation (Symptomatic NOH In Patients With MSA; Announced May 2023) | Theravance Biopharma, Inc. | Discontinued | Discontinued | NET Reuptake inhibitor |
Trials recruiting now
6 registered interventional multiple system atrophy trials — none recruiting at present. Browse all on ClinicalTrials.gov →
Frequently asked
- How many drugs are in development for multiple system atrophy?
- 2 compounds from 2 companies are in active clinical development for multiple system atrophy.
- What are the next multiple system atrophy trial readouts?
- Upcoming catalysts include Emrusolmin (2H 2027).